Claims for Patent: 6,281,230

Summary for Patent: 6,281,230

Title:	Isoindolines, method of use, and pharmaceutical compositions
Abstract:	Substituted 1-oxo-2-(2,6-dioxopiperidin-3-yl)isoindolines are useful in treating inflammation, inflammatory disease, autoimmune disease, and oncogenic or cancerous conditions in a mammal. Typical embodiments are 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline and 1-oxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4-aminoisoindoline.
Inventor(s):	Muller; George W. (Bridgewater, NJ), Stirling; David I. (Branchburg, NJ), Chen; Roger Shen-Chu (Edison, NJ)
Assignee:	Celgene Corporation (Warren, NJ)
Application Number:	09/543,809
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,281,230
Patent Claims:	1. A method of treating inflammation, inflammatory disease or autoimmune disease in a mammal which comprises administering thereto an effective amount of a compound of the formula: ##STR7## in which R.sup.6 is hydrogen or methyl. 2. The method according to claim 1 in which said compound has the formula: ##STR8## 3. The method according to claim 2 wherein said disease is rheumatoid arthritis. 4. The method according to claim 2 wherein said disease is osteoarthritis. 5. The method according to claim 2 wherein said disease is inflammatory bowel disease. 6. The method according to claim 5 wherein said inflammatory bowel disease is Crohn's disease. 7. The method according to claim 5 wherein said inflammatory bowel disease is ulcerative colitis. 8. The method according to claim 2 wherein said disease is an arthritic condition. 9. The method according to claim 2 wherein said disease is sepsis. 10. The method according to claim 2 wherein said disease is lupus. 11. The method according to claim 2 wherein said disease is erythema nodosum leprosum. 12. The method according to claim 2 wherein said compound is administered orally or parenterally. 13. The method according to claim 2 wherein said compound is administered in combination with a therapeutic agent. 14. The method according to claim 2 in which said compound is administered in the form of a physiologically acceptable non-toxic acid addition salt. 15. The method according to claim 2 in which said compound has the R-configuration. 16. The method according to claim 2 in which said compound has the S-configuration. 17. The method according to claim 2 in which said compound is administered in a single or multiple dosage regimen as a pharmaceutical composition containing from 1 to 100 mg. of said compound. 18. A method of treating an oncogenic or cancerous condition in a mammal which comprises administering thereto an effective amount of a compound of the formula: ##STR9## in which R.sup.6 is hydrogen or methyl. 19. The method according to claim 18 in which said compound has the formula: ##STR10## 20. The method according to claim 19 wherein said compound is administered orally or parenterally. 21. The method according to claim 19 in which said compound is administered in combination with a therapeutic agent. 22. The method according to claim 21 wherein said therapeutic agent is a steroid, neoplastic agent or antibiotic. 23. The method according to claim 19 in which said compound is administered in the form of a physiologically acceptable non-toxic acid addition salt. 24. The method according to claim 19 in which said compound has the R-configuration. 25. The method according to claim 19 in which said compound has the S-configuration. 26. The method according to claim 19 in which said compound is administered in a single or multiple dosage regimen as a pharmaceutical composition containing from 1 to 100 mg. of said compound.